{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:00:21Z","timestamp":1789639221193,"version":"4.0.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.08.025","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T17:49:01Z","timestamp":1631728141000},"page":"238-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-2610","authenticated-orcid":false,"given":"Leiah J.","family":"Brigitha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ejca.2021.08.025_bib1","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood Oncology group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41375-020-01024-0","article-title":"Progress against childhood and adolescent acute lymphoblastic leukaemia in The Netherlands, 1990-2015","volume":"35","author":"Reedijk","year":"2021","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ejca.2021.08.025_bib3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's Oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.025_bib4","series-title":"Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia","author":"H\u00f8jfeldt","year":"2020"},{"issue":"7","key":"10.1016\/j.ejca.2021.08.025_bib5","first-page":"942","article-title":"L-asparaginase in the treatment of neoplastic diseases in children","volume":"31","author":"Jaffe","year":"1971","journal-title":"Canc Res"},{"issue":"5690","key":"10.1016\/j.ejca.2021.08.025_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/bmj.1.5690.191","article-title":"L-asparaginase in treatment of acute leukaemia and lymphosarcoma","volume":"1","author":"Beard","year":"1970","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mpo.2950020405","article-title":"Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia","volume":"2","author":"Sutow","year":"1976","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mpo.2950040202","article-title":"Repeated use of L-asparaginase in multi-drug therapy of childhood leukemia","volume":"4","author":"Trueworthy","year":"1978","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.08.025_bib9","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group","volume":"39","author":"Ertel","year":"1979","journal-title":"Canc Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pbc.21213","article-title":"Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines","volume":"50","author":"Su","year":"2008","journal-title":"Pediatr Blood Canc"},{"issue":"Pt 1","key":"10.1016\/j.ejca.2021.08.025_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3570321","article-title":"Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells","volume":"357","author":"Aslanian","year":"2001","journal-title":"Biochem J"},{"issue":"20","key":"10.1016\/j.ejca.2021.08.025_bib12","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1021\/acs.biochem.0c00116","article-title":"Mechanism of catalysis by l-asparaginase","volume":"59","author":"Lubkowski","year":"2020","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.ejca.2021.08.025_bib13","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3324\/haematol.2018.206433","article-title":"Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study","volume":"104","author":"Rizzari","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pbc.20713","article-title":"Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941)","volume":"47","author":"Jarrar","year":"2006","journal-title":"Pediatr Blood Canc"},{"issue":"7","key":"10.1016\/j.ejca.2021.08.025_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.08.025_bib16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.08.025_bib17","series-title":"Drug Resistance in Leukemia and Lymphoma III","first-page":"621","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","author":"Asselin","year":"1999"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.0306-5251.2001.01464.x","article-title":"Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries","volume":"52","author":"Albertsen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2021.08.025_bib19","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403143","article-title":"Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL","volume":"17","author":"Appel","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2021.08.025_bib21","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.025_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ejca.2021.08.025_bib23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00432-019-02854-x","article-title":"Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002","volume":"145","author":"Karachunskiy","year":"2019","journal-title":"J Canc Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.08.025_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27083","article-title":"Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: a randomized multicenter study of the Dutch Childhood Oncology Group","volume":"65","author":"van der Sluis","year":"2018","journal-title":"Pediatr Blood Canc"},{"issue":"9","key":"10.1016\/j.ejca.2021.08.025_bib26","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ejca.2021.08.025_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26686","article-title":"Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation","volume":"64","author":"Tram Henriksen","year":"2017","journal-title":"Pediatr Blood Canc"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.025_bib28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2016.149195","article-title":"Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients","volume":"102","author":"Sassen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2021.08.025_bib29","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.109413","article-title":"Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia","author":"Tong","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.025_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.2001.19.5.1297","volume":"19","author":"Rizzari","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.08.025_bib32","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejca.2021.08.025_bib33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.20.02370","article-title":"Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children\u2019s Oncology Group Trial AALL0331","volume":"39","author":"Mattano","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.08.025_bib34","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3324\/haematol.2017.165845","article-title":"Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951","volume":"102","author":"Mondelaers","year":"2017","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.ejca.2021.08.025_bib35","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.025_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study","author":"Albertsen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.08.025_bib37","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.1998.16.8.2840","article-title":"Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study","volume":"16","author":"Harris","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.025_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.08.025_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.08.025_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MPH.0b013e31827e7f89","article-title":"long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the Indonesian WK-ALL-2000 protocol","volume":"35","author":"Widjajanto","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.08.025_bib41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.025_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2021.08.025_bib43","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.025_bib44","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12185-019-02599-w","article-title":"Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Usami","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejca.2021.08.025_bib46","series-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","first-page":"1176","author":"Avramis","year":"2006"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.025_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.22217","article-title":"Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol","volume":"54","author":"Suzuki","year":"2010","journal-title":"Pediatr Blood Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.08.025_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MPH.0b013e3180640d54","article-title":"Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"29","author":"Salzer","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.025_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000977","article-title":"Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion","volume":"5","author":"Baruchel","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.08.025_bib51","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.025_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O'Connor","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejca.2021.08.025_bib54","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2002-08-2446","article-title":"Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL","volume":"101","author":"Stams","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.08.025_bib55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","article-title":"Relation between age, immunophenotype and in\u00a0vitro drug resistance in 395 children with acute lymphoblastic leukemia \u2013 implications for treatment of infants","volume":"12","author":"Pieters","year":"1998","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejca.2021.08.025_bib56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bjh.13160","volume":"168","author":"Hastings","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2005-07-2930","article-title":"The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia","volume":"107","author":"Holleman","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejca.2021.08.025_bib58","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"Pieters","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.025_bib59","first-page":"24","article-title":"A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia","volume":"91","author":"Rizzari","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2021.08.025_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2021.08.025_bib61","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children\u2019s Oncology group study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:49Z","timestamp":1760733289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921005529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":61,"alternative-id":["S0959804921005529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}